[go: up one dir, main page]

WO2024184461A3 - Small molecule fsh receptor modulators - Google Patents

Small molecule fsh receptor modulators Download PDF

Info

Publication number
WO2024184461A3
WO2024184461A3 PCT/EP2024/056026 EP2024056026W WO2024184461A3 WO 2024184461 A3 WO2024184461 A3 WO 2024184461A3 EP 2024056026 W EP2024056026 W EP 2024056026W WO 2024184461 A3 WO2024184461 A3 WO 2024184461A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
receptor modulators
fsh receptor
fsh
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/056026
Other languages
French (fr)
Other versions
WO2024184461A2 (en
Inventor
Philip Stewart Turnbull
Zhaoning Zhu
Jacek Stalewski
Rachel Marie GILLARD
Theodore Henry Noah BULLESS
Tom Scott CARTER
Adele FAULKNER
Catherine Jane GREENAWAY
Cristina Lecci
Matthew Robert MILLS
Carlos Arróniz SALAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Priority to CN202480006431.0A priority Critical patent/CN120693335A/en
Priority to KR1020257029869A priority patent/KR20250157379A/en
Priority to IL322905A priority patent/IL322905A/en
Priority to AU2024231935A priority patent/AU2024231935A1/en
Publication of WO2024184461A2 publication Critical patent/WO2024184461A2/en
Publication of WO2024184461A3 publication Critical patent/WO2024184461A3/en
Priority to CONC2025/0011478A priority patent/CO2025011478A2/en
Priority to MX2025010463A priority patent/MX2025010463A/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are small molecule follicle-stimulating hormone (FSH) receptor modulators, methods of making them, and therapeutic methods using them.
PCT/EP2024/056026 2023-03-08 2024-03-07 Small molecule fsh receptor modulators Pending WO2024184461A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202480006431.0A CN120693335A (en) 2023-03-08 2024-03-07 Small molecule FSH receptor modulators
KR1020257029869A KR20250157379A (en) 2023-03-08 2024-03-07 small molecule FSH receptor modulators
IL322905A IL322905A (en) 2023-03-08 2024-03-07 Small molecule fsh receptor modulators
AU2024231935A AU2024231935A1 (en) 2023-03-08 2024-03-07 Small molecule fsh receptor modulators
CONC2025/0011478A CO2025011478A2 (en) 2023-03-08 2025-08-26 Small molecule FSH receptor modulators
MX2025010463A MX2025010463A (en) 2023-03-08 2025-09-04 Small molecule fsh receptor modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363450847P 2023-03-08 2023-03-08
US63/450,847 2023-03-08
US202363606514P 2023-12-05 2023-12-05
US63/606,514 2023-12-05

Publications (2)

Publication Number Publication Date
WO2024184461A2 WO2024184461A2 (en) 2024-09-12
WO2024184461A3 true WO2024184461A3 (en) 2024-10-31

Family

ID=90364175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/056026 Pending WO2024184461A2 (en) 2023-03-08 2024-03-07 Small molecule fsh receptor modulators

Country Status (8)

Country Link
KR (1) KR20250157379A (en)
CN (1) CN120693335A (en)
AU (1) AU2024231935A1 (en)
CO (1) CO2025011478A2 (en)
IL (1) IL322905A (en)
MX (1) MX2025010463A (en)
TW (1) TW202435866A (en)
WO (1) WO2024184461A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098283A1 (en) * 2008-02-08 2009-08-13 N.V. Organon (dihydro)pyrrolo[2,1-a]isoquinolines
WO2010136438A1 (en) * 2009-05-27 2010-12-02 N.V. Organon (dihydro) imidazoiso (5, 1-a) quinolines as fsh receptor agonists for the treatment of fertility disorders
WO2011008597A1 (en) * 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
WO2014209978A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Imidazole compounds as modulators of fshr and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4511042B2 (en) 1998-08-07 2010-07-28 メルク セローノ ソシエテ アノニム FSH mimics for the treatment of infertility
EP1307193A1 (en) 2000-07-27 2003-05-07 Affymax Research Institute Agonists of follicle stimulating hormone activity
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
WO2015196335A1 (en) 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098283A1 (en) * 2008-02-08 2009-08-13 N.V. Organon (dihydro)pyrrolo[2,1-a]isoquinolines
WO2010136438A1 (en) * 2009-05-27 2010-12-02 N.V. Organon (dihydro) imidazoiso (5, 1-a) quinolines as fsh receptor agonists for the treatment of fertility disorders
WO2011008597A1 (en) * 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
WO2014209978A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Imidazole compounds as modulators of fshr and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON ROSS C. ET AL: "Small Molecule Follicle-Stimulating Hormone Receptor Agonists and Antagonists", FRONTIERS IN ENDOCRINOLOGY, vol. 9, 23 January 2019 (2019-01-23), CH, pages 1 - 9, XP093160234, ISSN: 1664-2392, DOI: 10.3389/fendo.2018.00757 *
PLOYPRADITH P ET AL: "Further developments in the synthesis of lamellarin alkaloids via direct metal-halogen exchange", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 44, no. 7, 10 February 2003 (2003-02-10), pages 1363 - 1366, XP004405221, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(02)02887-3 *

Also Published As

Publication number Publication date
AU2024231935A1 (en) 2025-07-17
IL322905A (en) 2025-10-01
CO2025011478A2 (en) 2025-11-19
CN120693335A (en) 2025-09-23
TW202435866A (en) 2024-09-16
WO2024184461A2 (en) 2024-09-12
KR20250157379A (en) 2025-11-04
MX2025010463A (en) 2025-10-01

Similar Documents

Publication Publication Date Title
EP4563199A3 (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2019222449A8 (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
CA2220461A1 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
WO2023288241A8 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
PH12021550964A1 (en) Protein tyrosine-tyrosine analogs and methods of using the same.
AU2561195A (en) Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
NO20050018L (en) Lasofoxifene tablets and coatings
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
MX2024006064A (en) Crystalline composition of tildacerfont and methods of use and preparation thereof.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2022175414A8 (en) Multispecific anti-tcr delta variable 1 antibodies
WO2024184461A3 (en) Small molecule fsh receptor modulators
JP2017533257A5 (en)
WO2023002415A3 (en) Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
WO2024044778A3 (en) Novel modulators of fshr and uses thereof
WO2024026059A3 (en) Delivery of therapeutic alkaloid compounds
WO2021067628A3 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
WO2023081194A3 (en) Methods for treating alzheimer's disease
WO2003011395A3 (en) Method of utilizing neurotrophins to manipulate reproductive capacity
NO20060241L (en) Freeze-dried FSH / LH formulations
WO2024011189A3 (en) Methods of treating disease using anti-il1rap antibodies and antibody drug conjugates
WO1995016709A3 (en) Anti-mullerian hormone receptor polypeptides and antibodies thereto
CA3153302A1 (en) Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24710693

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024231935

Country of ref document: AU

Ref document number: 822875

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202480006431.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 202517065866

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202591837

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2024231935

Country of ref document: AU

Date of ref document: 20240307

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 822875

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2501005535

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 322905

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11202504676Q

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202504676Q

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 1020257029869

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: P2025-02814

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025017177

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 202480006431.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: DZP2025001351

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2024710693

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202517065866

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024710693

Country of ref document: EP

Effective date: 20251008

ENP Entry into the national phase

Ref document number: 2024710693

Country of ref document: EP

Effective date: 20251008

ENP Entry into the national phase

Ref document number: 2024710693

Country of ref document: EP

Effective date: 20251008

ENP Entry into the national phase

Ref document number: 2024710693

Country of ref document: EP

Effective date: 20251008